In eyes with macular edema secondary to central retinal or hemiretinal vein occlusion, is switching treatment after a poor response to bevacizumab or aflibercept associated with improvement in visual acuity or central subfield thickness?
In this secondary analysis of a nonrandomized trial in which 49 patients with central retinal or hemiretinal vein occlusion responded poorly to treatment with bevacizumab or aflibercept, eyes with treatment switched from bevacizumab to aflibercept at month 6 showed improvement in visual acuity and central subfield thickness at month 12. Few eyes had a poor response to aflibercept, and therefore, treatment was switched to dexamethasone in few.
Eyes with central retinal or hemiretinal vein occlusion that have a poor response to bevacizumab may benefit after switching to aflibercept treatment; however, the small sample size and lack of controls in this study preclude definitive conclusions.
Information is needed to assess switching treatment in eyes with a poor response to 6 months of monthly administration of aflibercept or bevacizumab for macular edema from central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).
To investigate visual acuity letter score (VALS) and central subfield thickness (CST) changes from month 6 to 12 among eyes with a poor response at month 6 to monthly dosing of aflibercept or bevacizumab in the Study of Comparative Treatments for Retinal Vein Occlusion 2.
Design, Setting, and Participants
This secondary analysis of the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) was conducted at 66 private practice or academic centers in the United States. Participants included 49 patients (1 eye from each patient evaluated) with CRVO- or HRVO-associated macular edema and a protocol-defined poor response to aflibercept or bevacizumab treatment at month 6. The first month 6 visit occurred on September 8, 2015, and the last month 12 visit occurred on October 24, 2016.
Treatment in eyes receiving monthly aflibercept was switched to a dexamethasone implant at month 6 and, if needed, at months 9, 10, or 11. Treatment in eyes receiving monthly bevacizumab was switched to aflibercept at months 6, 7, and 8, and then to a treat-and-extend aflibercept regimen until month 12.
Main Outcomes and Measures
Change from month 6 to 12 in VALS and CST.
Of the 49 participants at month 6, aflibercept treatment had failed in 14 (6 [43%] women; mean [SD] age, 70.4 [13.0] years). Bevacizumab treatment had failed in 35 patients (16 [46%] women; mean age, 70.0 [13.2] years). In 14 eyes with treatment switched from aflibercept to dexamethasone, the estimated mean change from month 6 to 12 in VALS was 2.63 (95% CI, −3.29 to 8.56; P = .37) and 46.0 μm (95% CI, −80.9 to 172.9 μm; P = .46) for CST. In 35 eyes with treatment switched from bevacizumab to aflibercept, the estimated mean change from month 6 to 12 in VALS was 10.27 (95% CI, 6.05-14.49; P < .001) and −125.4 μm (95% CI, −180.9 to −69.9 μm; P < .001) for CST.
Conclusions and Relevance
Eyes treated with aflibercept after a poor response to bevacizumab had improvement in VALS and CST. Few eyes had a poor response to aflibercept, and therefore, few eyes were switched to dexamethasone. Caution is warranted in interpreting these results owing to the small number of eyes and lack of comparison groups. These factors preclude definitive assessment of whether the switching strategy is superior to maintaining treatment.
Ip MS, Oden NL, Scott IU, et al. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study. JAMA Ophthalmol. Published online December 27, 2018. doi:10.1001/jamaophthalmol.2018.6111
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: